Unlike IDH-wildtype gliomas, the IDH-mutant gliomas may also demonstrate decreased glutamate (Glu), myo-inositol (mI), glutathione (GSH), and glucose+taurine.21,25 The IDH1 mutation also influences glutamate metabolism, with expression of glutamate dehydrogenase 1 (GDH1) and glutamate dehydrogenase 2 (GDH2) mRNA significantly higher in IDH1-mutant gliomas than in IDH1-wildtype gliomas.47 IDH1-mutant gliomas also expressed decreased mRNA level of branched chain amino acid transaminase 1 (BCAT1). The gene discussed is GLUD1; the disease is central nervous system cancer.